Frontiers in Aging Neuroscience最新文献

{"title":"Stools from a human APOEe2 donor reduces amyloid and tau pathology and increases neuroinflammation in a 3xTg AD mouse model.","authors":"Moira Marizzoni, Benjamin B Tournier, Claire Chevalier, Samantha Saleri, Aurélien Lathuilière, Kelly Ceyzériat, Arthur Paquis, Rahel Park, Emma Troesch, Annamaria Cattaneo, Philippe Millet, Giovanni B Frisoni","doi":"10.3389/fnagi.2025.1539067","DOIUrl":"https://doi.org/10.3389/fnagi.2025.1539067","url":null,"abstract":"<p><strong>Background: </strong>The mechanisms underlying the protective effect of the e2 variant of the APOE gene (APOEe2) against Alzheimer's disease (AD) have not been elucidated. We altered the microbiota of 3xTgAD mice by fecal microbiota transplantation from a human APOEe2 donor (e2-FMT) and tested the effect of microbiota perturbations on brain AD pathology.</p><p><strong>Methods: </strong>FMT of bacteria isolated from stools of untreated 3xTgAD mice (M-FMT) or e2-FMT were transplanted in 15-month-old 3xTgAD mice. FMT was done alone or in combination with antibiotic and proton-pump inhibitor following the Microbiota Transfer Therapy protocol (MTT). The effect of donor (M or e2) and transplantation protocol (FMT or MTT) on hippocampal amyloid, tau pathology and neuroinflammation were assessed at the end of the treatment.</p><p><strong>Results: </strong>e2-FMT reduced amyloid, and tau pathology as well as increased neuroinflammation as compared with M-FMT. MTT was associated with reduced number of Aβ40+ plaques and tau pathology. Low levels of amyloid were associated with high levels of pro-inflammatory molecules in e2-FMT mice. These associations were partially attenuated by MTT.</p><p><strong>Conclusion: </strong>Bacteria from a human APOEe2 donor reduced AD pathology and increased neuroinflammation in mice suggesting that the gut microbiota may be a mediator of the protective effect of APOEe2.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1539067"},"PeriodicalIF":4.1,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11868276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delirium following mechanical thrombectomy for ischemic stroke - individuals at risk, imaging biomarkers and prognosis.","authors":"Marianne Hahn, Lavinia Brockstedt, Sonja Gröschel, Katharina Geschke, Nils F Grauhan, Marc A Brockmann, Ahmed E Othman, Klaus Gröschel, Timo Uphaus","doi":"10.3389/fnagi.2025.1486726","DOIUrl":"https://doi.org/10.3389/fnagi.2025.1486726","url":null,"abstract":"<p><strong>Aim: </strong>Post-stroke-delirium has been linked to worse outcome in patients with acute cerebrovascular disease; identification of individuals at risk may prevent delirium and thereby improve outcome. We investigate prognosis and factors associated with post-stroke-delirium in patients with large vessel occlusion (LVO) ischemic stroke treated by mechanical thrombectomy (MT).</p><p><strong>Methods: </strong>747 patients (53.4% female) prospectively enrolled in the Gutenberg-Stroke-Study from May 2018-November 2022 were analyzed with regard to diagnosis of delirium. Group comparison of patient-, stroke- and treatment characteristics as well as computed tomography(CT)-imaging based parameters of cerebral atrophy (global cortical atrophy [GCA], posterior atrophy [Koedam], medial temporal lobe atrophy [MTA] scores) and white matter lesions (Fazekas score) was conducted. Independent predictors of delirium and the association of delirium with functional outcome at 90-day follow-up was investigated by multiple logistic regression analyses.</p><p><strong>Results: </strong>We report 8.2% of patients (61/747) developing delirium following MT of LVO. Independent predictors were older age (aOR[95%CI] per year: 1.034[1.005-1.065], <i>p</i> = 0.023), male sex (aOR[95%CI]: 2.173[1.182-3.994], <i>p</i> = 0.012), general anesthesia during MT (aOR[95%CI]: 2.455[1.385-4.352], <i>p</i> = 0.002), infectious complications (aOR[95%CI]: 1.845[1.031-3.305], <i>p</i> = 0.039), \"other determined\" etiology of stroke (aOR[95%CI]: 2.424[1.100-5.345], <i>p</i> = 0.028), and a MTA score exceeding age-specific cut-offs (aOR[95%CI]: 2.126[1.065-4.244], <i>p</i> = 0.033). Delirium was independently associated with worse functional outcome (aOR[95%CI]: 2.902[1.005-8.383], <i>p</i> = 0.049) at 90-day follow-up.</p><p><strong>Conclusion: </strong>Delirium is independently associated with worse functional outcome after MT of LVO, stressing the importance of screening and preventive measures. Besides conventional risk factors, pathological MTA scores and use of general anesthesia during MT may be easy-to-apply criteria to identify individuals at risk of delirium and implement prevention strategies.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1486726"},"PeriodicalIF":4.1,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11868270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Convergent reductions in interhemispheric functional, structural and callosal connectivity in Parkinson's disease.","authors":"Erlei Wang, Yujing Jia, Luqi Cheng, Chengjie Mao, Yiqing Bao, Junkang Shen, Yuanchao Zhang, Guohua Fan","doi":"10.3389/fnagi.2025.1512130","DOIUrl":"10.3389/fnagi.2025.1512130","url":null,"abstract":"<p><strong>Background: </strong>Abnormal interhemispheric functional connectivity is frequently reported in Parkinson's disease (PD), but its structural basis remains unclear. This study aimed to investigate changes in interhemispheric functional, structural, and callosal connectivity, as well as their interrelationships, in PD patients.</p><p><strong>Methods: </strong>The study included 57 PD patients and 50 healthy controls (HCs). Interhemispheric functional connectivity was evaluated using voxel mirrored homotopic connectivity (VMHC) derived from resting-state functional MRI, while structural connectivity was measured through homotopic cortical thickness covariance from T1-weighted MRI. The corpus callosum (CC), connecting bilateral regions with VMHC differences, was assessed using fractional anisotropy (FA) from diffusion MRI. Pearson's correlation was used to evaluate the interrelationships among imaging data and their clinical relevance.</p><p><strong>Results: </strong>Compared to HCs, PD patients showed reduced VMHC and interhemispheric structural connectivity in similar brain regions, displaying a positive correlation trend between these measures. The affected regions encompassed the bilateral sensorimotor cortices (precentral gyrus, postcentral gyrus, and paracentral lobule) and posterior cortical areas, including the superior parietal lobule, supramarginal gyrus, precuneus, middle occipital gyrus, fusiform gyrus, as well as the superior and middle temporal gyri. FA in the CC, connecting regions with reduced VMHC, was also lower in PD patients. Additionally, interhemispheric structural, functional, and callosal connectivity reductions were, respectively, related to cognitive impairment, motor dysfunctions, and disease duration in PD.</p><p><strong>Conclusion: </strong>The study identified convergent reductions in interhemispheric functional, structural and callosal connectivity in PD patients, emphasizing the strong link between structural and functional brain abnormalities. Our findings may provide new insights into the pathophysiology of PD.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1512130"},"PeriodicalIF":4.1,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering novel mitochondrial signatures: multi-omics analysis uncovers cross-disease markers and oligodendrocyte pathways in Alzheimer's disease and glioblastoma.","authors":"Xuan Xu, Jiaqi Wang, Tong Chen, Shuaibin Wang, Fei Wang, Junwen He, Xiang-Yu Meng, Yin Shen","doi":"10.3389/fnagi.2025.1536142","DOIUrl":"10.3389/fnagi.2025.1536142","url":null,"abstract":"<p><strong>Introduction: </strong>Alzheimer's disease (AD) and glioblastoma (GBM) are severe neurological disorders that pose significant global healthcare challenges. Despite extensive research, the molecular mechanisms, particularly those involving mitochondrial dysfunction, remain poorly understood. A major limitation in current studies is the lack of cell-specific markers that effectively represent mitochondrial dynamics in AD and GBM.</p><p><strong>Methods: </strong>In this study, we analyzed single-cell transcriptomic data using 10 machine learning algorithms to identify mitochondria-associated cell-specific markers. We validated these markers through the integration of gene expression and methylation data across diverse cell types. Our dataset comprised single-nucleus RNA sequencing (snRNA-seq) from AD patients, single-cell RNA sequencing (scRNA-seq) from GBM patients, and additional DNA methylation and transcriptomic data from the ROSMAP, ADNI, TCGA, and CGGA cohorts.</p><p><strong>Results: </strong>Our analysis identified four significant cross-disease mitochondrial markers: <i>EFHD1, SASH1, FAM110B,</i> and <i>SLC25A18</i>. These markers showed both shared and unique expression profiles in AD and GBM, suggesting a common mitochondrial mechanism contributing to both diseases. Additionally, oligodendrocytes and their interactions with astrocytes were implicated in disease progression, particularly through the APP signaling pathway. Key hub genes, such as <i>HS6ST3</i> and <i>TUBB2B</i>, were identified across different cellular subpopulations, highlighting a cell-specific co-expression network linked to mitochondrial function.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1536142"},"PeriodicalIF":4.1,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-pharmacological treatment of Alzheimer's disease: an update.","authors":"Shaofen Wang, Haochen Xu, Guangdong Liu, Limei Chen","doi":"10.3389/fnagi.2025.1527242","DOIUrl":"10.3389/fnagi.2025.1527242","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a neurodegenerative disorder that significantly impairs memory, cognitive function, and the ability to perform daily tasks. The pathological features of AD include β-amyloid plaques, neurofibrillary tangles, and neuronal loss. Current AD treatments target pathological changes but often fail to noticeably slow disease progression and can cause severe complications, limiting their effectiveness. In addition to therapies targeting the core pathology of AD, a more comprehensive approach may be needed for its treatment. In recent years, non-pharmacological treatments such as physical therapy, exercise therapy, cell therapy, and nanoparticles have shown great potential in mitigating disease progression and alleviating clinical symptoms. This article reviews recent advances in non-pharmacological treatment approaches for AD, highlighting their contributions to AD management and facilitating the exploration of novel therapeutic strategies.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1527242"},"PeriodicalIF":4.1,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of protective effects of olanzapine on impaired learning and memory using behavioral tests in a rat model of Alzheimer's disease.","authors":"Somayeh Komaki, Parsa Amiri, Samaneh Safari, Ebrahim Abbasi, Fatemeh Ramezani-Aliakbari, Mandana Golipoor, Masoumeh Kourosh-Arami, Masome Rashno, Alireza Komaki","doi":"10.3389/fnagi.2025.1376074","DOIUrl":"10.3389/fnagi.2025.1376074","url":null,"abstract":"<p><strong>Introduction: </strong>Evidence suggests that oxidative stress plays a critical role in the pathogenesis and progression of Alzheimer's disease (AD). Consequently, antioxidants may mitigate neurotoxicity induced by beta-amyloid (Aβ) and potentially reduce cell death. Previous research has demonstrated that olanzapine (OLZ) possesses antioxidant and neuroprotective properties. In this study, we investigated the protective and therapeutic effects of OLZ on an animal model of AD induced by Aβ using behavioral assessments.</p><p><strong>Methods: </strong>Rats were randomly assigned to one of five groups (<i>n</i> = 10 rats per group): a control group, a sham group that received an intracerebrovascular (ICV) injection of phosphate-buffered saline (the solvent for Aβ), an AD group that received an ICV injection of Aβ, an OLZ group that received OLZ <i>via</i> gavage for two months, and an AD + OLZ group that received OLZ for one month before and one month after AD induction.</p><p><strong>Results: </strong>We used the Elevated Plus Maze (EPM), Novel Object Recognition Test (NORT), Barnes Maze (BM), Passive Avoidance Test (PAT), and Morris Water Maze (MWM) to assess behavioral performance in the experimental rats. Aβ administration impaired cognition and increased anxiety-like behavior. Treatment with OLZ improved cognitive decline and reduced anxiety-like behavior in Aβ-infused rats.</p><p><strong>Conclusion: </strong>Our findings suggest that OLZ can restore cognitive performance and alleviate anxiety-like behavior following Aβ injection. Thus, OLZ may have both preventive and therapeutic potential for AD and could be considered a viable pharmacological option.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1376074"},"PeriodicalIF":4.1,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11865076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study insights in the role of PGC-1α in neurological diseases: mechanisms and therapeutic potential.","authors":"Mi-Bo Tang, Yi-Xuan Liu, Zheng-Wei Hu, Hai-Yang Luo, Shuo Zhang, Chang-He Shi, Yu-Ming Xu","doi":"10.3389/fnagi.2024.1454735","DOIUrl":"10.3389/fnagi.2024.1454735","url":null,"abstract":"<p><p>Peroxisome proliferator-activated receptor-<i>γ</i> coactivator-1α (PGC-1α), which is highly expressed in the central nervous system, is known to be involved in the regulation of mitochondrial biosynthesis, metabolic regulation, neuroinflammation, autophagy, and oxidative stress. This knowledge indicates a potential role of PGC-1α in a wide range of functions associated with neurological diseases. There is emerging evidence indicating a protective role of PGC-1α in the pathogenesis of several neurological diseases. As such, a deeper and broader understanding of PGC-1α and its role in neurological diseases is urgently needed. The present review provides a relatively complete overview of the current knowledge on PGC-1α, including its functions in different types of neurons, basic structural characteristics, and its interacting transcription factors. Furthermore, we present the role of PGC-1α in the pathogenesis of various neurological diseases, such as intracerebral hemorrhage, ischemic stroke, Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Huntington's disease, and other PolyQ diseases. Importantly, we discuss some compounds or drug-targeting strategies that have been studied to ameliorate the pathology of these neurological diseases and introduce the possible mechanistic pathways. Based on the available studies, we propose that targeting PGC-1α could serve as a promising novel therapeutic strategy for one or more neurological diseases.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"16 ","pages":"1454735"},"PeriodicalIF":4.1,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bidirectional relationship between depression and activities of daily living and longitudinal mediation of cognitive function in patients with Parkinson's disease.","authors":"Yue Xu, Durong Chen, Meiqi Dong, Yun Zhang, Hongmei Yu, Yanqing Han","doi":"10.3389/fnagi.2025.1513373","DOIUrl":"10.3389/fnagi.2025.1513373","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the bidirectional relationship between depression and activities of daily living (ADL) in Parkinson's disease (PD) patients and explore the mediating role of cognitive function over time.</p><p><strong>Methods: </strong>Data from 892 PD patients from the Parkinson's Progression Markers Initiative (PPMI) database were included in this study, and depression, cognitive function, and ADL were measured using the Geriatric Depression Scale (GDS-15), Montreal Cognitive Assessment Scale (MoCA), and Unified Parkinson's Disease Rating Scale, Part II (UPDRS II) respectively. The cross-lagged panel model (CLPM) was employed to analyze the reciprocal relationship between depression and ADL. Then, we explored the mediating role of cognitive function in the bidirectional relationship between depression and ADL in patients with PD, and the mediation effect test was carried out using a bias-corrected nonparametric percentile bootstrap approach.</p><p><strong>Results: </strong>Depression in patients with PD predicted their subsequent ADL (<i>β</i> = 0.079, <i>p</i> < 0.01), and ADL also predicted their subsequent depression (<i>β</i> = 0.069, <i>p</i> < 0.05), In addition, Bootstrap analysis showed that cognitive function played a significant mediating role in prediction of depression to ADL in patients with PD (<i>β</i> = 0.006, <i>p</i> = 0.074, 95%CI = 0.001 ~ 0.014), and cognitive function also played a significant mediating role in prediction of depression to ADL (<i>β</i> = 0.006, <i>p</i> = 0.067, 95%CI = 0.001 ~ 0.013).</p><p><strong>Conclusion: </strong>There is a bidirectional relationship between depression and ADL in patients with PD. Furthermore, we found that cognitive function mediates the relationship that exists between depression and ADL in patients with PD. Interventions aimed at enhancing cognitive function could potentially lessen the vicious cycle of depression and ADL in PD, thus improving patient quality of life (QOL).</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1513373"},"PeriodicalIF":4.1,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring cognitive and neuroimaging profiles of dementia subtypes of individuals with dementia in the Democratic Republic of Congo.","authors":"Jean Ikanga, Saranya Sundaram Patel, Megan Schwinne, Caterina Obenauf, Emmanuel Epenge, Guy Gikelekele, Nathan Tshengele, Immaculee Kavugho, Samuel Mampunza, Lelo Mananga, Charlotte E Teunissen, Julio C Rojas, Brandon Chan, Argentina Lario Lago, Joel H Kramer, Adam L Boxer, Andreas Jeromin, Emile Omba, Alvaro Alonso, Alden L Gross","doi":"10.3389/fnagi.2025.1552348","DOIUrl":"10.3389/fnagi.2025.1552348","url":null,"abstract":"<p><strong>Objective: </strong>The 2024 Alzheimer's Association (AA) research diagnostic criteria for Alzheimer's Disease (AD) considers fluid biomarkers, including promising blood-based biomarkers for detecting AD. This study aims to identify dementia subtypes and their cognitive and neuroimaging profiles in older adults with dementia in the Democratic Republic of Congo (DRC) using biomarkers and clinical data.</p><p><strong>Methods: </strong>Forty-five individuals with dementia over 65 years old were evaluated using the Community Screening Instrument for Dementia and the informant-based Alzheimer's Questionnaire. Core AD biomarkers (Aβ42/40 and p-tau181) and non-specific neurodegeneration biomarkers (NfL, GFAP) were measured in blood plasma. Neuroimaging structures were assessed using magnetic resonance imaging (MRI). Dementia subtypes were determined based on plasma biomarker pathology and vascular markers. Biomarker cutoff scores were identified to optimize sensitivity and specificity. Individuals were stratified into one of four dementia subtypes-AD only, non-AD vascular, non-AD other, or mixed - based on combinations of abnormalities in these markers.</p><p><strong>Results: </strong>Among the 45 individuals with dementia, mixed dementia had the highest prevalence (42.4%), followed by AD-only (24.4%), non-AD other dementia (22.2%), and non-AD vascular dementia subtypes (11.1%). Both cognitive and neuroimaging profiles aligned poorly with biomarker classifications in the full sample. Cognitive tests varied across dementia subtypes. The cognitive profile of the AD-only and mixed groups suggested relatively low cognitive performance, while the non-AD and other groups had the best scores on average.</p><p><strong>Conclusion: </strong>Consistent with studies in other settings, our preliminary findings suggest that neurodegenerative plasma biomarkers may help to identify dementia subtypes and provide insight into cognitive and neuroimaging profiles among older adults in the DRC.</p>","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1552348"},"PeriodicalIF":4.1,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11860979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: To Know or Not to Know: causes and evolution of lack of awareness of cognitive decline in neurodegenerative diseases, volume II.","authors":"Federica Cacciamani, Kristy A Nielson, Bernard J Hanseeuw, Geoffroy P Gagliardi, Patrizia Vannini","doi":"10.3389/fnagi.2025.1568173","DOIUrl":"10.3389/fnagi.2025.1568173","url":null,"abstract":"","PeriodicalId":12450,"journal":{"name":"Frontiers in Aging Neuroscience","volume":"17 ","pages":"1568173"},"PeriodicalIF":4.1,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}